Get the Stockscreener App
2.03
0.98%
-0.02
Pre-market:
2.05
0.02
+0.99%
Actuate Therapeutics Inc stock is traded at $2.03, with a volume of 51,229.
It is down -0.98% in the last 24 hours and down -22.52% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$2.05
Open:
$2.05
24h Volume:
51,229
Relative Volume:
0.32
Market Cap:
$48.57M
Revenue:
-
Net Income/Loss:
$-21.54M
P/E Ratio:
-2.0497
EPS:
-0.9904
Net Cash Flow:
$-19.60M
1W Performance:
+1.00%
1M Performance:
-22.52%
6M Performance:
-70.83%
1Y Performance:
-75.75%
1-Day Range:
$1.93
$2.06
1-Week Range:
$1.8501
$2.78
52-Week Range:
$1.58
$9.22
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
2.03 | 49.05M | 0 | -21.54M | -19.60M | -0.9904 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
ACTU Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Advances PipelineEarnings Revision Upgrade - newsline.com
Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained - TipRanks
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion - Investing.com
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Actuate’s elraglusib to be evaluated in BEACON2 neuroblastoma trial - Investing.com
Actuate Therapeutics to Evaluate Elraglusib in BEACON2 Clinical Trial for Relapsed Neuroblastoma in Partnership with Cancer Research UK Clinical Trials Unit - Quiver Quantitative
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma - GlobeNewswire
Actuate Therapeutics (ACTU) Surges 6.59% as Biotech Momentum Builds Above Key SupportSystematic Flow - newsline.com
Elraglusib shows significant survival benefits in metastatic pancreatic cancer combined with standard chemo. - Pluang
Actuate presents elraglusib trial data at ASCO meeting By Investing.com - Investing.com South Africa
Actuate presents elraglusib trial data at ASCO meeting - Investing.com
Actuate Therapeutics Reports Positive Survival Outcomes for Elraglusib in Combination with Standard Chemotherapies for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO 2026 - Quiver Quantitative
Actuate Therapeutics Announces ASCO Poster Presentations - GlobeNewswire
Actuate Therapeutics (ACTU) Declines 2.88% as Stock Nears Key Support ZoneEarnings Beat Stocks - The Legal Advocate
Actuate Therapeutics (ACTU) Holds Near Support Amid Low VolatilityVolume Spike Alerts - The Legal Advocate
Actuate Therapeutics (ACTU) Drops 4.09% as Shares Test Critical $2.00 Support LevelFlat Correction - newsline.com
ACTU Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseGuidance vs Actual - Newser
Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com India
Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart
Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor - TipRanks
Actuate Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
Actuate Therapeutics, Inc.Common stock (NQ: ACTU - The Chronicle-Journal
Actuate Therapeutics (ACTU) Holds Near Support After Modest UptickCrowd Breakout Signals - Newser
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
ACTU Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Actuate Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Actuate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO) - The Globe and Mail
Actuate Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
TradingKey - TradingKey
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Actuate Wins FDA Clearance for Oral Elraglusib Trial - TipRanks
Actuate Therapeutics (NASDAQ: ACTU) gets FDA IND ok but flags cash risk - Stock Titan
Actuate Therapeutics Announces FDA Clearance of IND for - GlobeNewswire
Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks
Actuate Therapeutics Adds Oncology Veteran Martin Huber to Board as Elraglusib Advances - citybiz
Actuate Therapeutics appoints Martin Huber to board - Investing.com
Actuate Therapeutics appoints Martin Huber to board By Investing.com - Investing.com Australia
Actuate Therapeutics Appoints Dr. Martin Huber as Independent Director to Strengthen Leadership Team - Quiver Quantitative
Cancer drug developer Actuate taps ex-Mersana CEO for board seat - Stock Titan
Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026 - marketscreener.com
Actuate Therapeutics (ACTU) price target decreased by 17.00% to 21.16 - MSN
Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1% - MarketBeat
Actuate Therapeutics announces public offering of common stock - MSN
Why did Actuate Therapeutics (ACTU) stock jump over 14% after hours? - MSN
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - whbl.com
Actuate Therapeutics Inc Stock (ACTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Actuate Therapeutics Inc Stock (ACTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| THOMSON TODD S | Director |
Jan 05 '26 |
Sale |
5.80 |
280,000 |
1,624,000 |
904,795 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):